To be honest I am relieved - that at least one PBS option exists for those who can not fork out $5000 a month ... and sad and disappointed. Why?
My understanding is that both Palbociclib ( Ibrance ) and Ribociclib ( Kisqali ) were approved by the PBAC and submitted to ministry for PBS.
What has happened to Palbociclib ??
I ask because ribociclib (although a good inhibitor of CDK4/6) use IS PROBLEMATIC, it has a reported 7% incidence of QT prologation ( QT interval prolongation has been associated with sudden death).
To the extent of my knowledge this has NOT been reported with Palbociclib ( Ibrance )
http://www.ascopost.com/issues/december-25-2017/ribociclib-doubles-progression-free-survival-in-premenopausal-breast-cancer/Are we being sold the most commercial effective option at a time when budgets are announced and elections are brewing ?
This takes nothing away from BCNA ongoing efforts to get these drugs to Australian women.